As early as 1997, studies showed that IL-2(+) and CD80(+) tumor vaccines could protect and prolong the survival time of a higher proportion of sarcoma-bearing mice compared with IL-2(+) tumor vaccines (82). Here, CD80 is linked to neoplasm.